KALV News and Press, KalVista Pharmaceuticals Inc. From 03/11/24

2024-03-11 06:37:30 ET More on KalVista Pharmaceticals KalVista Is Still Cheap After Phase 3 Hereditary Angioedema Data KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade) KalVista: On Demand Oral Treatment For HAE Signifies D...

- Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema - - CEO transition supports ongoing evolution into commercial company - KalVista Pharmaceuticals, Inc . (...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 HAEi Regional Conference meeting taking...

2024-03-07 06:51:28 ET More on KalVista Pharmaceticals KalVista Is Still Cheap After Phase 3 Hereditary Angioedema Data KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade) KalVista: On Demand Oral Treatment For HAE Signifies D...

– Planned transition reflects evolution to commercial company with sebetralstat for HAE – – NDA filing remains on track for H1 2024; Europe and Japan filings H2 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutica...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that its management will participate in a fireside chat at the Leerink Partners 2024 Glo...

– Patient perspectives revealed frequent treatment delays, suboptimal clinical outcomes and substantial anxiety associated with injectable on-demand treatments, including those who received long-term prophylaxis - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage ...

– 94% of attacks required only one dose to achieve primary endpoint - – Further analyses demonstrate efficacy across all levels of attack severity - – Additional safety data reinforces flexibility of dosing - KalVista Pharmaceuticals, Inc. (NASDAQ:...

– Provides entry to UK Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines – – Late-breaking sebetralstat phase 3 data to be presented at the upcoming 2024 American Academy of ...

2024-02-16 16:31:07 ET More on KalVista Pharmaceticals KalVista Is Still Cheap After Phase 3 Hereditary Angioedema Data KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade) KalVista Pharmaceuticals up 16%, prices $160M offering...